Skip to content

Clinical trial on enoxaparine and Aspirin effects on mobility problems of stroke patients

Clinical trial on Enoxaparine and Aspirin effects on mobility problems of non-hemorrhagic stroke patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201109067495N1
Enrollment
60
Registered
2011-12-10
Start date
2009-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-hemorrhagic stroke. Cerebral Infarction

Interventions

Intervention 1: 60 non-hemorrhagic stroke patients were randomly assigned into two groups: Experiment and control groups. While experiment group were intradermally received 5000 units heparin every 6
Treatment - Drugs
Treatment - Other
60 non-hemorrhagic stroke patients were randomly assigned into two groups: Experiment and control groups. While experiment group were intradermally received 5000 units heparin every 6 hours or 4000-80
60 non-hemorrhagic stroke patients were randomly assigned into two groups: Control group were received only 100-325 mg aspirin.

Sponsors

Vice Chancellor for Research, Shahrekord Univrsity of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Stroke patients, with confirmed nonhemorrhagic stroke diagnosed by computed tomography scan (CT- scan) or magnetic resonance imaging (MRI), in Kashani Hospital in Shahrekord. ; Exclusion criteria: Patients with hemorrhagic ischemic stroke; trauma; secondary neurologic complications; metabolic disorders (hypokalemia; hyponatremia …)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Baseline muscular powers of patients. Timepoint: At the beginning of study. Method of measurement: Prothrombin time (PT) and partial thromboplastin time (PTT).

Secondary

MeasureTime frame
Muscular power of Limbs. Timepoint: ?after 3 days. Method of measurement: Prothrombin time and Tromboplastin time.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Masoud Amiri

Shahrekord University of Medical Sciences

masoud.amiri@yahoo.com ; m.amiri@skums.ac.ir+98 38 1333 3710

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026